<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03477721</url>
  </required_header>
  <id_info>
    <org_study_id>NUMANCAN</org_study_id>
    <nct_id>NCT03477721</nct_id>
  </id_info>
  <brief_title>The Role of the Muscle-nervous System Interface in Cancer Cachexia</brief_title>
  <acronym>NUMANCAN</acronym>
  <official_title>The Role of the Muscle-nervous System Interface in Cancer Cachexia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Roma La Sapienza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Roma La Sapienza</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sarcopenia is an important component of cachexia associated with cancer, and their high
      incidence in cancer patients emphasizes the need for a better understanding of its
      mechanisms, which can result in better therapeutic interventions to reverse this situation
      and improve the prognosis. Our hypothesis is that the plasma concentration of IL-6 and
      c-terminal agrin is directly correlated with the loss of muscle mass and development of
      cachexia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The agrin is a protein that acts on neuromuscular junctions (NMJs) promoting stabilization of
      same, which results in the maintenance and growth of muscle fibers, but the cleavage of
      agrin, a process by which is formed the agrin fragment C-terminus (CAF), has been linked to
      the development of sarcopenia, because its presence is directly linked to the reduction in
      the number of muscle fibers, increasing the heterogeneity of fiber size, presence of Central
      cores and increasing the proportion of type I fibers and consequently a greater degradation
      of lean body mass. Studies in mice show that the greatest cleavage of agrin carries on
      development of sarcopenia and human studies report that individuals with higher serum levels
      of sarcopenia CAF compared to individuals without sarcopenia.

      Therefore, aiming at the complexity of cancer associated with the cachexia and the great
      importance of the maintenance of lean body mass to a better prognosis in disease, is of
      fundamental importance to elucidate the role of CAF and the factors associated with
      sarcopenia, the possible use of these proteins for diagnosis and the contribution that this
      clarification could bring in clinical therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 16, 2018</start_date>
  <completion_date type="Anticipated">April 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">April 16, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Agrin fragment c-terminus CAF in cancer and cancer cachexia</measure>
    <time_frame>1 month</time_frame>
    <description>To measure the contents of agrin fragment c-terminus (CAF) in plasma of patient with cancer and cancer cachexia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Agrin fragment c-terminus CAF in cancer sarcopenia</measure>
    <time_frame>1 month</time_frame>
    <description>To analyze correlation between Agrin fragment c-terminus CAF and the lean body mass (CT-scan estimated) of patients with cancer and with cancer cachexia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Agrin fragment c-terminus CAF and IL-6 levels</measure>
    <time_frame>1 month</time_frame>
    <description>To correlate levels of agrin fragment c-terminus (CAF) and IL-6 plasma levels in patients with cancer and with cancer cachexia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Agrin fragment c-terminus (CAF) and IL-6 and lean body mass</measure>
    <time_frame>1 month</time_frame>
    <description>To correlate levels of agrin fragment c-terminus (CAF) and IL-6 with the lean body mass</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cachexia; Cancer; Sarcopenia</condition>
  <arm_group>
    <arm_group_label>Group with cancer cachexia (CTB)</arm_group_label>
    <description>For diagnosis of cachexia it will be used the following criteria (Evans et al., 2008)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group without cancer cachexia (TB)</arm_group_label>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples: determination of: serum C-reactive protein, albumin, creatinine and
      haemoglobin concentrations. Agrin fragment c-terminus and IL-6 will be carried out using
      specific ELISA kits.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Oure sample will be selected between cancer patient of Rome Umberto I Hospital
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  cancer diagnosis

        Exclusion Criteria:

          -  continuously use of anti-inflammatory medications;

          -  present renal and/or liver failure,

          -  AIDS,

          -  inflammatory bowel disease or chronic inflammatory processes not related to cachexia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Alessandro Laviano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Medicine, Sapienza University of Rome, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laviano Alessandro</last_name>
    <phone>+390649973902</phone>
    <email>alessandro.laviano@uniroma1.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Clinical Medicine, Sapienza University of Rome</name>
      <address>
        <city>Rome</city>
        <zip>00185</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Laviano, MD</last_name>
      <phone>+390649973902</phone>
      <email>alessandro.laviano@uniroma1.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Argilés JM, Alvarez B, López-Soriano FJ. The metabolic basis of cancer cachexia. Med Res Rev. 1997 Sep;17(5):477-98. Review.</citation>
    <PMID>9276862</PMID>
  </reference>
  <reference>
    <citation>Argilés JM, Busquets S, Toledo M, López-Soriano FJ. The role of cytokines in cancer cachexia. Curr Opin Support Palliat Care. 2009 Dec;3(4):263-8. doi: 10.1097/SPC.0b013e3283311d09. Review.</citation>
    <PMID>19713854</PMID>
  </reference>
  <reference>
    <citation>Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001 Feb 17;357(9255):539-45. Review.</citation>
    <PMID>11229684</PMID>
  </reference>
  <reference>
    <citation>Batista ML Jr, Peres SB, McDonald ME, Alcantara PS, Olivan M, Otoch JP, Farmer SR, Seelaender M. Adipose tissue inflammation and cancer cachexia: possible role of nuclear transcription factors. Cytokine. 2012 Jan;57(1):9-16. doi: 10.1016/j.cyto.2011.10.008. Epub 2011 Nov 17. Review.</citation>
    <PMID>22099872</PMID>
  </reference>
  <reference>
    <citation>Belizário JE, Fontes-Oliveira CC, Borges JP, Kashiabara JA, Vannier E. Skeletal muscle wasting and renewal: a pivotal role of myokine IL-6. Springerplus. 2016 May 13;5:619. doi: 10.1186/s40064-016-2197-2. eCollection 2016. Review.</citation>
    <PMID>27330885</PMID>
  </reference>
  <reference>
    <citation>Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, Guttridge D, Jatoi A, Kalantar-Zadeh K, Lochs H, Mantovani G, Marks D, Mitch WE, Muscaritoli M, Najand A, Ponikowski P, Rossi Fanelli F, Schambelan M, Schols A, Schuster M, Thomas D, Wolfe R, Anker SD. Cachexia: a new definition. Clin Nutr. 2008 Dec;27(6):793-9. doi: 10.1016/j.clnu.2008.06.013. Epub 2008 Aug 21.</citation>
    <PMID>18718696</PMID>
  </reference>
  <reference>
    <citation>Fan Y, Mao R, Yang J. NF-κB and STAT3 signaling pathways collaboratively link inflammation to cancer. Protein Cell. 2013 Mar;4(3):176-85. doi: 10.1007/s13238-013-2084-3. Epub 2013 Mar 13. Review.</citation>
    <PMID>23483479</PMID>
  </reference>
  <reference>
    <citation>Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011 May;12(5):489-95. doi: 10.1016/S1470-2045(10)70218-7. Epub 2011 Feb 4. Review.</citation>
    <PMID>21296615</PMID>
  </reference>
  <reference>
    <citation>Fearon KC, Moses AG. Cancer cachexia. Int J Cardiol. 2002 Sep;85(1):73-81. Review.</citation>
    <PMID>12163211</PMID>
  </reference>
  <reference>
    <citation>Fearon KC, Voss AC, Hustead DS; Cancer Cachexia Study Group. Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr. 2006 Jun;83(6):1345-50.</citation>
    <PMID>16762946</PMID>
  </reference>
  <reference>
    <citation>Gonzalez-Freire M, de Cabo R, Studenski SA, Ferrucci L. The Neuromuscular Junction: Aging at the Crossroad between Nerves and Muscle. Front Aging Neurosci. 2014 Aug 11;6:208. doi: 10.3389/fnagi.2014.00208. eCollection 2014. Review.</citation>
    <PMID>25157231</PMID>
  </reference>
  <reference>
    <citation>Hettwer S, Dahinden P, Kucsera S, Farina C, Ahmed S, Fariello R, Drey M, Sieber CC, Vrijbloed JW. Elevated levels of a C-terminal agrin fragment identifies a new subset of sarcopenia patients. Exp Gerontol. 2013 Jan;48(1):69-75. doi: 10.1016/j.exger.2012.03.002. Epub 2012 Mar 11.</citation>
    <PMID>22433628</PMID>
  </reference>
  <reference>
    <citation>Kalinkovich A, Livshits G. Sarcopenia--The search for emerging biomarkers. Ageing Res Rev. 2015 Jul;22:58-71. doi: 10.1016/j.arr.2015.05.001. Epub 2015 May 8. Review.</citation>
    <PMID>25962896</PMID>
  </reference>
  <reference>
    <citation>Kern KA, Norton JA. Cancer cachexia. JPEN J Parenter Enteral Nutr. 1988 May-Jun;12(3):286-98. Review.</citation>
    <PMID>3292798</PMID>
  </reference>
  <reference>
    <citation>Kujawski M, Kortylewski M, Lee H, Herrmann A, Kay H, Yu H. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest. 2008 Oct;118(10):3367-77. doi: 10.1172/JCI35213.</citation>
    <PMID>18776941</PMID>
  </reference>
  <reference>
    <citation>Kumar NB, Kazi A, Smith T, Crocker T, Yu D, Reich RR, Reddy K, Hastings S, Exterman M, Balducci L, Dalton K, Bepler G. Cancer cachexia: traditional therapies and novel molecular mechanism-based approaches to treatment. Curr Treat Options Oncol. 2010 Dec;11(3-4):107-17. doi: 10.1007/s11864-010-0127-z. Review.</citation>
    <PMID>21128029</PMID>
  </reference>
  <reference>
    <citation>Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008 Jul 24;454(7203):436-44. doi: 10.1038/nature07205. Review.</citation>
    <PMID>18650914</PMID>
  </reference>
  <reference>
    <citation>Mignogna MD, Fedele S, Lo Russo L, Lo Muzio L, Bucci E. Immune activation and chronic inflammation as the cause of malignancy in oral lichen planus: is there any evidence ? Oral Oncol. 2004 Feb;40(2):120-30. Review.</citation>
    <PMID>14693234</PMID>
  </reference>
  <reference>
    <citation>Okada F. Inflammation-related carcinogenesis: current findings in epidemiological trends, causes and mechanisms. Yonago Acta Med. 2014 Jun;57(2):65-72. Epub 2014 Jul 30. Review.</citation>
    <PMID>25324587</PMID>
  </reference>
  <reference>
    <citation>Roxburgh CS, McMillan DC. Cancer and systemic inflammation: treat the tumour and treat the host. Br J Cancer. 2014 Mar 18;110(6):1409-12. doi: 10.1038/bjc.2014.90. Epub 2014 Feb 18. Review.</citation>
    <PMID>24548867</PMID>
  </reference>
  <reference>
    <citation>Scherbakov N, Knops M, Ebner N, Valentova M, Sandek A, Grittner U, Dahinden P, Hettwer S, Schefold JC, von Haehling S, Anker SD, Joebges M, Doehner W. Evaluation of C-terminal Agrin Fragment as a marker of muscle wasting in patients after acute stroke during early rehabilitation. J Cachexia Sarcopenia Muscle. 2016 Mar;7(1):60-7. doi: 10.1002/jcsm.12068. Epub 2015 Oct 27.</citation>
    <PMID>27066319</PMID>
  </reference>
  <reference>
    <citation>Tisdale MJ. Cancer cachexia. Curr Opin Gastroenterol. 2010 Mar;26(2):146-51. doi: 10.1097/MOG.0b013e3283347e77. Review.</citation>
    <PMID>19918173</PMID>
  </reference>
  <reference>
    <citation>Srdic D, Plestina S, Sverko-Peternac A, Nikolac N, Simundic AM, Samarzija M. Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer-chemotherapy toxicity and prognostic value. Support Care Cancer. 2016 Nov;24(11):4495-502. doi: 10.1007/s00520-016-3287-y. Epub 2016 May 28.</citation>
    <PMID>27236439</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2018</study_first_submitted>
  <study_first_submitted_qc>March 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2018</study_first_posted>
  <last_update_submitted>March 18, 2018</last_update_submitted>
  <last_update_submitted_qc>March 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Roma La Sapienza</investigator_affiliation>
    <investigator_full_name>Alessandro Laviano</investigator_full_name>
    <investigator_title>Alessandro Laviano, MD associate professor of Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>Agrin Fragment C-terminus (CAF)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcopenia</mesh_term>
    <mesh_term>Cachexia</mesh_term>
    <mesh_term>Wasting Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>We are still evaluate a researcher to analyze data collected</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

